Rocbrutinib Clinical Trials

3 actively recruiting trials

Also known as: LP-168

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1

Top Sponsors

Guangzhou Lupeng Pharmaceutical Company LTD.3

Indications

Cancer3
Diffuse Large B-cell Lymphoma(DLBCL)1
Mantle Cell Lymphoma1
B-Cell Non-Hodgkin Lymphoma1

Other3 trials

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 3

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Phase 2

Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.